When: Confirmed breakout above $272.07 with MACD histogram expanding above 1.0

Then: Full position restoration

When: Weekly close below $256.28 with volume expansion confirming technical break

Then: Sell

When: Major adverse talc verdict exceeding $5B framework settlement

Then: Sell

When: Forward EPS revision toward $10-11

Then: Sell

HOLD - Do not initiate short; maintain core long; only trim on confirmed close below 263 if mandated

• Shorting JNJ creates unlimited upside risk for a short position versus bounded downside for a long position in a low-beta, AAA-rated name
• 50 SMA at 256.28 functions as a hard institutional floor where pension funds, sovereign wealth, and income mandates have buy-on-dip protocols
• MACD histogram at 0.22 has not crossed negative; no confirmed bearish cross exists; no break of 50 SMA; no lower-low sequence
• Polymarket pricing December Fed cut at 11% and September at only 2%, contradicting the aggressive rotation thesis
• Intra-Cellular acquisition ($14.6 billion) has been in reported numbers for over a year; 96% of Innovative Medicine growing at 14%+ year-over-year per Trefis analysis
• RSI at 54.6 is neutral, not bearish; MACD line at 4.27 still above signal at 4.04
• Two consecutive red sessions on 7.3 million shares volume represent normal post-rally profit-taking, not distribution
• Only trim if mandated by risk-budgeting: no more than 15-20% of position weight, only on confirmed daily close below 263, in tranches not market orders

→ vs aggressive: Short SELL at 268 with stop at 272 is the riskiest structure for a conservative mandate—unlimited downside exposure to avoid a 1.5-2% pullback in a low-beta name, with stop sitting precisely at the squeeze entry point if Jackson Hole prints dovish

→ vs neutral: HOLD recommendation is too passive and fails to take a position on whether the current trim is justified; does not address what to do with active exposure, only the meta-question of waiting

Trim to 80 percent of current weight over 10-15 sessions; set 270 as trim-add ceiling; keep no-add rule above 265; accelerate to 75 percent if price closes below 263; drop short-trade stop mechanics; time execution around Jackson Hole rather than into it.

• Technical deterioration is real — break below 10 EMA, MACD compression, two red sessions with elevated volume — and warrants action, not dismissal.
• The aggressive analyst's framing is binary (full SELL) but the actual trade on the table is a trim, not a short; attacking a short proposal misrepresents the position being evaluated.
• Macro event risk at Jackson Hole makes aggressive trimming into Powell's speech reckless; Polymarket pricing December cut odds at 11 percent with 3.5 percentage point downward drift over the past week signals hawkish repricing.
• The conservative analyst's "do nothing" position is procrastination dressed as prudence; waiting for all confirmations (50 SMA test, MACD cross, bullish reversal) means trimming at lows instead of near current levels.
• The floor argument is overstated — in a hawkish-surprise scenario, the 50 SMA at 256 is tested by ETF and pension-fund rebalancing flows, not defended by dip-buyers.
• Growth that is recognized in a 21.6 forward multiple is growth already paid for; the 96 percent of Innovative Medicine growing above 14 percent undermines the bear case but doesn't support a buy.
• IMAAVY approval extends the rare-disease franchise and provides a soft floor (fresh buy-side talking point) but cannot move a 640 billion market cap on its own.
• 80 percent preserves meaningful defensive exposure through both scenarios — violent defensive rotation on dovish surprise, or continued pressure from hawkish repricing on long-end yields.
• The no-add rule above 265 is the one discipline element from the original plan worth keeping exactly as written.

→ vs aggressive: Framing is binary (full SELL) but the actual proposal is a trim to 60-70 percent; attacking a short-trade construction misrepresents the trade on the table and oversells the courage of the bearish case.

→ vs aggressive: The 10 EMA break, MACD compression, and elevated volume are valid signals, but shorting an AAA-rated, low-beta, dividend-aristocrat name into a binary Jackson Hole event with the 50 SMA nine points below is genuinely reckless regardless of technical quality.

→ vs conservative: "Do nothing" is not capital preservation — by the time all confirmations stack up, the trim becomes a panicked trim at 256 instead of a planned trim at 268, giving back 3 to 5 percent of unrealized gains.

→ vs conservative: Waiting for Jackson Hole to play out before committing full trim execution is right, but applying that logic to "do nothing" now means missing the opportunity to trim at better levels before the catalyst resolves.

→ vs conservative: The floor that holds is not the same as a stock that goes up — a 640 billion market cap name can chop flat between 256 and 270 for two to three months, which is opportunity cost, not capital preservation.

→ vs conservative: Trefis analysis showing 96 percent of Innovative Medicine growing above 14 percent undermines the aggressive analyst's growth arithmetic, but doesn't automatically support a buy case at 21.6 forward multiple.